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Dear Editor,  
A 42-year-old lady was diagnosed to have International Staging System (ISS) stage II 
IgGλ myeloma in 2007. She achieved a minor response after VAD (vincristine, 
Adriamycin, dexamethasone) induction, then partial remission (PR) after further 
induction with VTD (bortezomib, thalidomide and dexamethasone), and finally 
immunofixation-negative complete remission (CR) after autologous stem cell 
transplantation (ASCT) in Dec, 2007, which was confirmed by bone marrow examination. 
(Figure 1A) She was maintained on thalidomide 50mg/day. Serial serum protein 
electrophoresis (SPE) remained negative until Dec, 2009 when SPE and immunofixation 
of serum (IFX) showed reappearance of IgGλ with the paraprotein level measuring 
3.8g/L. However, she was completely asymptomatic and free of CRAB (hypercalcemia, 
renal failure, anaemia and bone disease) complications. Moreover, SPE showed that the 
“recurrent” IgGλ was in a different position on electrophoresis, (Figure 1B) and hence a 
diagnosis of oligoclonal reconstitution was made instead of disease relapse. In the 
absence of salvage chemotherapy, the low level of IgGλ paraprotein persisted between 3-
4g/L until Oct, 2010 when repeat SPE and IFX showed disappearance of paraprotein. The 
patient remained in immunofixation-ve CR as of Oct, 2012. 
We have reported frequent oligoclonal reconstitution, which was associated with 
superior event-free survival in myeloma patients. (Chim et al, 2010a) The paraproteins in 
oligoclonal reconstitutions often have an isotype different from the original paraprotein. 
(Mark et al, 2008) Recurrence of a paraprotein of the same isotype as diagnosis after 
achievement of CR will raise the possibility of myeloma relapse, implicating subsequent 
salvage treatment. Moreover, possibility of relapse is especially valid when the 
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paraprotein emerged at 2 years after ASCT, and became measurable. However, when the 
“recurrent” paraprotein was reviewed, it occupied a different position on electrophoresis 
gel, and hence consistent with an oligoclonal reconstitution instead of relapse. Finally, 
this oligoclonal paraprotein level remained low, and eventually disappeared, thereby 
confirming an oligoclonal reconstitution instead of relapse.  
A better way to confirm if the recurrent paraprotein of the same diagnostic 
paraprotein as part of disease relapse is to perform two-dimensional gel electrophoresis, 
which is not available in our institute. Moreover, the diagnosis of “relapse” might have 
triggered salvage treatment in some centers. Finally, as there are many on-going clinical 
trials in myeloma, the detection of relapse is an important end-point for event-free or 
progression-free survival analysis. 
 Oligoclonal reconstitution is becoming prevalent in this era of targeted therapy in 
myeloma as the depth of response has been increased. Oligoclonal reconstitution was first 
reported in patients achieving CR after ASCT prior to the advent of novel agents. (Zent et 
al, 1998) However, in myeloma patients receiving induction therapy with novel agents 
followed by ASCT, as many as 25% - 33% of patients were found to develop oligoclonal 
reconstitution. (Chim et al, 2010b; Fernández de Larrea et al, 2011)  
In conclusion, oligoclonal reconstitution in myeloma is an important differential 
diagnosis to relapse, impacts important end-points such as CR in clinical trials, and 
obviates the inappropriate consideration of salvage therapy. It is essential to review the 
serum protein electrophoresis and immunofixation gels to confirm the status of remission.  
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Legend 
Fig 1A Shows the achievement of CR after ASCT, occurrence of oligoclonal 
reconstitution and finally complete resolution of oligoclonal reconstitution.  
Figure 1B showed monoclonal IgG at diagnosis by immunofixation (upper left), 
resolution of M-protein at the time of complete remission (upper right), recurrence of a 
new monoclonal IgG of a different molecular size due to oligoclonal reconstitution (blue 
arrow) as compared with the monoclonal IgG at diagnosis (dark arrow) (lower left), and 
finally, complete resolution of the oligoclonal reconstitution (lower right). 
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